Amyloidosis Market

Market Overview:

The 7 major amyloidosis markets reached a value of US$ 5,251.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 20,697.4 Million by 2034, exhibiting a growth rate (CAGR) of 13.3% during 2024-2034.

The amyloidosis market has been comprehensively analyzed in IMARC's new report titled "Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amyloidosis is a group of rare diseases that occur when abnormal proteins, called amyloid fibrils, build up in various tissues and organs throughout the body. These amyloid fibrils are made of misfolded proteins that clump together, forming insoluble deposits which can interfere with the normal function of the affected tissues and organs. Some of the common symptoms include fatigue, weight loss, edema, shortness of breath, numbness or tingling in the hands and feet, skin changes like bruising or purplish patches, etc. Amyloid deposits can also cause damage to specific organs, leading to symptoms such as kidney failure, heart failure, liver enlargement, gastrointestinal problems, etc. The diagnosis of amyloidosis involves a combination of tests and procedures to detect the presence of amyloid deposits in the body and determine the type and location of the disease. Numerous diagnostic investigations, such as blood tests, urine tests, imaging tests, including X-rays, CT scans, MRIs, etc., and tissue biopsies are required to confirm the accumulation of amyloid fibrils. A definitive diagnosis of amyloidosis typically involves a biopsy of affected tissue, such as the liver, kidney, or bone marrow, to confirm the diagnosis.

The rising prevalence of several associated risk factors, including genetic mutations, chronic inflammation or infection, overproduction of specific proteins, etc., is primarily driving the amyloidosis market. In addition to this, the escalating utilization of immunomodulatory drugs, such as lenalidomide and thalidomide, in the treatment of amyloidosis to target the abnormal plasma cells and reduce the production of immunoglobulin light chains is further creating a positive outlook for the market. Moreover, the increasing application of mass spectrometry-based proteomic analysis for the detection of amyloid deposits is bolstering the amyloidosis market. Additionally, several key players are making extensive investments in R&D initiatives for the launch of novel drugs and therapies for effective treatment owing to the complex nature of amyloidosis as a disease. This, in turn, is also propelling the market growth. Furthermore, the widespread adoption of monoclonal antibodies, such as daratumumab and elotuzumab, to reduce the level of abnormal proteins in the blood and improve organ function in patients is acting as another significant growth-inducing factor. Besides this, the inflating usage of combined therapy, including cytoreductive, plasma cell-directed chemotherapy, immunotherapy, etc., to achieve rapid and deep hematologic remission to cease the progression of end-organ damage is expected to drive the amyloidosis market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the amyloidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for amyloidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amyloidosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the amyloidosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the amyloidosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current amyloidosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the amyloidosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the amyloidosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the amyloidosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of amyloidosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amyloidosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amyloidosis by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amyloidosis by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with amyloidosis across the seven major markets?
• What is the size of the amyloidosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of amyloidosis?
• What will be the growth rate of patients across the seven major markets?
   

Amyloidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for amyloidosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amyloidosis market?
• What are the key regulatory events related to the amyloidosis market?
• What is the structure of clinical trial landscape by status related to the amyloidosis market?
• What is the structure of clinical trial landscape by phase related to the amyloidosis market?
• What is the structure of clinical trial landscape by route of administration related to the amyloidosis market?